Read More Pharma Industry News Acrivon Therapeutics strengthens precision oncology pipeline with ACR-368 Phase 2b success and new AP3-enabled candidates Find out how Acrivon Therapeutics is advancing precision oncology with positive ACR-368 Phase 2b data, EU trial expansion, and new AP3-enabled pipeline candidates. bySoujanya RaviJanuary 8, 2026